Citations

Showing 10 of 108083 citations.

Perioperative pressure injury prevention: National Pressure Injury Advisory Panel root cause analysis toolkit 3.0
Tescher, Ann, Deppisch, Michelle, Munro, Cassendra, Jorgensen, Vince, Cuddigan, Janet

Mayo Clinic

Journal of Wound Care | December 8, 2022 | Volume: 31 | Issue: Sup12 | Pages: S4-S9

10.12968/jowc.2022.31.sup12.s4 | PMID 36475846 Get It

Objectives: Operating room-related pressure injuries (ORPI) are particularly challenging to examine for several reasons. Time in the OR is often a distinct event within the hospitalisation, and discovery of an ORPI may occur between several hours and up to 5 days postoperatively. The National Pressure Injury Advisory Panel (NPIAP) first developed a root cause analysis (RCA) toolkit in 2017 as a systematic strategy for investigating the root causes of facility-acquired pressure injury (PI). The purpose of this 2021 RCA toolkit update was to address an expanded investigation of medical device-related PIs (MDRPIs), both inside and outside the OR, as well as the specific PI prevention issues of the perioperative area. Methods: Clinicians have been using the 2017 toolkit as a basis for ongoing quality improvement tracking, since it provides more accurate information than data extractions from patient health records. A small working group consisting of NPIAP board and panel members developed investigative questions to identify the ORPI root causes and compliance with best practices for the entire perioperative experience. Results: Action items are linked to evidence-based recommendations from the NPIAP/European Pressure Ulcer Advisory Panel/Pan Pacific Pressure Injury Alliance 2019 International Guideline and the Association of PeriOperative Registered Nurses (AORN) Guidelines for Perioperative Practice. A multidisciplinary clinician guide was also developed to identify practice gaps and to compile the information into an action plan for staff education and/or process improvement. Conclusion: The updated NPIAP RCA toolkit provides mechanisms for investigating, compiling and trending data as a basis for data-driven quality improvement. Using the enhanced investigative tools, the root causes of both MDRPIs and ORPIs can be better understood to target efforts to reduce their occurrence.
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Aniwan, Satimai , Santiago, Priscila , Loftus, Edward V. , Park, Sang Hyoung , Loftus, Edward V

Mayo Clinic

United European Gastroenterology Journal | December 8, 2022 | Volume: 10 | Issue: 10 | Pages: 1063-1076

10.1002/ueg2.12350 | PMID 36479863 Get It

Abstract Inflammatory bowel disease (IBD), which comprises Crohn's disease and ulcerative colitis, is an idiopathic inflammatory condition of the gastrointestinal tract. The incidence and prevalence of IBD are rapidly increasing worldwide, particularly in newly industrialized regions such as Asia. Although a large medical armamentarium is available for treating this chronic disease, IBD imposes a marked global disease burden. To understand the complex etiopathogenesis of this condition, it is important to consider the rapidly changing trends in its epidemiology in Asia. During the past few decades, the incidence and prevalence of IBD have significantly increased in both Asian countries and Asian immigrants in Western countries. In this review, we aimed to study and update the epidemiology of IBD in diverse Asian regions and among Asian immigrants in North America and Europe. Moreover, we highlighted that this population exhibits a unique disease phenotype, such as male predominance and high frequency of perianal fistula in Crohn's disease. Also, a different disease phenotype including more complicated disease such as perianal complications was noted in Asian Americans and Asian Europeans.
A review of testosterone supplementation and cardiovascular risk
Chirilă, Răzvan M. , Jhawar, Nikita , Chirilă, Răzvan

Mayo Clinic

Romanian Journal of Internal Medicine | December 8, 2022 | Volume: 61 | Issue: 1 | Pages: 35-40

10.2478/rjim-2022-0022 | PMID 36476654 Get It

Abstract Testosterone therapy is commonly utilized to treat hypogonadism. After diagnosis with morning serum testosterone level in patients with symptoms of hypogonadism, therapy has been shown to improve symptoms. Research focusing on cardiovascular risks associated with testosterone therapy has produced contradictory statements. We review trials that have investigated the impact of testosterone supplementation on heart failure, coronary artery disease, and myocardial ischemia.
Examination of Tobacco-Related Messaging and Tobacco Use over Time among U.S. Military Young Adults
Wang, Xin-Qun , Fahey, Margaret C. , Patten, Christi A. , Talcott, G. Wayne , Klesges, Robert C. , Little, Melissa A. , Fahey, Margaret C , Patten, Christi , Pebley, Kinsey , Mallawaarachchi, Indika V.

Mayo Clinic

Substance Use & Misuse | December 8, 2022 | Volume: 58 | Issue: 1 | Pages: 146-152

10.1080/10826084.2022.2151313 | PMID 36476101 Get It

Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution
Paczynski, Madeline , Day, Gregory S. , Day, Gregory S

Mayo Clinic

Journal of Primary Care & Community Health | December 8, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221141178 | PMID 36475976 Get It

An estimated 6.1 million Americans live with cognitive impairment—a number that is expected to triple by 2050. Alzheimer disease (AD) is the most common cause of impairment. The development of blood-based biomarkers capable of detecting pathological changes of AD in living patients has the potential to revolutionize the diagnostic approach to cognitive impairment by enabling screening for AD using accessible, non-invasive measures of amyloid and tau neuropathology, with accuracy that increasingly approaches that seen with “gold standard” positron emission tomography and cerebrospinal fluid measures. Demand for biomarker testing is expected to intensify with the emergence of effective treatments for AD and related dementias. Clinicians in all fields must prepare to meet this demand. Primary care practitioners are well positioned to support dementia diagnosis and management, including the application and interpretation of biomarkers. This article reviews the current uses of AD biomarkers and the potential applications of emerging blood-based AD biomarkers in clinical practice.
Association between Tumor Microbiome and Hypoxia across Anatomic Subsites of Head and Neck Cancers
Dhakal, Aastha , Upadhyay, Rituraj , Wheeler, Caroline E. , Karivedu, Vidhya , Gamez, Mauricio E. , Valentin, Sasha, Vanputten, Meade, Bhateja, Priyanka, Bonomi, Marcelo , Konieczkowski, David J. , Baliga, Sujith , Mitchell, Darrion , Grecula, J.C., Blakaj, Dukagjin , Jhawar, Sachin R. , Spakowicz, Daniel , Wheeler, Caroline , Bhateja, Priyanka , Bonomi, Marcelo , Mitchell, Darrion L , Jhawar, Sachin R , Spakowicz, Daniel , Hoyd, Rebecca , VanPutten, Meade, Denko, Nicholas C.

Mayo Clinic

International Journal of Molecular Sciences | December 8, 2022 | Volume: 23 | Issue: 24 | Pages: 15531

10.3390/ijms232415531 | PMID 36555172 Get It

Purpose/Objective(s): Microbiome has been shown to affect tumorigenesis by promoting inflammation. However, the association between the upper aerodigestive microbiome and head and neck squamous cell carcinoma (HNSCC) is not well established. Hypoxia is a modifiable factor associated with poor radiation response. Our study analyzed the HNSCC tumor samples from The Cancer Genome Atlas (TCGA) to investigate the relationship between different HNSCC tumor subsites, hypoxia, and local tumor microbiome composition. Results: A total of 357 patients were included [Oral cavity (OC) = 226, Oropharynx (OPx) = 53, and Larynx/Hypopharynx (LHPx) = 78], of which 12.8%, 71.7%, and 10.3%, respectively, were HPV positive. The mean (SD) hypoxia scores were 30.18 (11.10), 24.31 (14.13), and 29.53 (12.61) in OC, OPx, and LHPx tumors, respectively, with higher values indicating greater hypoxia. The hypoxia score was significantly higher for OC tumors compared to OPx (p = 0.044) and LHPx (p = 0.002). There was no significant correlation between hypoxia and HPV status. Pseudomonas sp. in OC, Actinomyces sp. and Sulfurimonas sp. in OPx, and Filifactor, Pseudomonas and Actinomyces sp. in LHPx had the strongest association with the hypoxia score. Materials/Methods: Tumor RNAseq samples from TCGA were processed, and the R package “tmesig” was used to calculate gene expression signature, including the Buffa hypoxia (BH) score, a validated hypoxia signature using 52 hypoxia-regulated genes. Microbe relative abundances were modeled with primary tumor location and a high vs. low tertile BH score applying a gamma-distributed generalized linear regression using the “stats” package in R, with adjusted p-value < 0.05 considered significant. Conclusions: In our study, oral cavity tumors were found to be more hypoxic compared to other head and neck subsites, which could potentially contribute to their radiation resistance. For each subsite, distinct microbial populations were over-represented in hypoxic tumors in a subsite-specific manner. Further studies focusing on an association between microbiome, hypoxia, and patient outcomes are warranted.
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT
Bilen, Mehmet Asım , Akintayo, Akinyemi A. , Abiodun-Ojo, Olayinka A. , Küçük, Ömer , Carthon, Bradley Curtis , Parent, Ephraim E. , Kucuk, Omer , Parent, Ephraim E , Liu, Y. , Schuster, David M.

Mayo Clinic

Cancers | December 8, 2022 | Volume: 14 | Issue: 24 | Pages: 6039

10.3390/cancers14246039 | PMID 36551525 Get It

Objectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, [68Ga]Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NePC). This study explores the utility of [68Ga]Ga-DOTATATE PET-CT to identify metastatic deposits in men with mCRPC and NePC and prognosticate disease progression. Methods: [68Ga]Ga-DOTATATE PET-CT was performed in 17 patients with mCRPC and of those, 2/17 had NePC. A semiquantitative analysis with standardized uptake values (SUV) (e.g., SUVmax, SUVmean) was performed for each metastatic lesion and reference background tissues. [68Ga]Ga-DOTATATE uptake in metastatic deposits was further classified as: mild (less than liver), moderate (up to liver average), or marked (greater than liver). Serial prostate-specific antigen measurements and patient survival were followed up to 3 years after PET imaging to assess response to standard of care treatment. Results: All patients had at least one metastatic lesion with identifiable [68Ga]Ga-DOTATATE uptake. Marked [68Ga]Ga-DOTATATE uptake was found in 7/17 patients, including both NePC patients, and all were non-responders to systemic therapy and died within the follow up period, with a mean time to death of 8.1 months. Three patients had mild [68Ga]Ga-DOTATATE uptake, and all were responders to systemic therapy and were alive 36 months after [68Ga]Ga-DOTATATE imaging. Conclusions: [68Ga]Ga-DOTATATE is able to identify mCRPC and NePC metastatic deposits, and lesions with [68Ga]Ga-DOTATATE uptake > liver may portend poor outcomes in patients with mCRPC.
Primary Hip Arthroscopy for Femoroacetabular Impingement Syndrome in Adolescents Improves Outcomes and Clinical Benefit Achievement Rates at Short‐Term Follow‐Up: A Multicenter Analysis
Maldonado, David R. , Kufta, Allison , Levy, Bruce A. , Okoroha, Kelechi R. , Gonzalez-Carta, Karina, Domb, Benjamin G. , Krych, Aaron J.

Mayo Clinic

Arthroscopy | December 8, 2022 | Volume: 39 | Issue: 5 | Pages: 1211-1219

10.1016/j.arthro.2022.11.020 | PMID 36572612 Get It

Purpose To report minimum 2‐year follow‐up patient‐reported outcome scores (PROs) and rates of achieving the minimal clinically important difference (MCID), the patient‐acceptable symptomatic state (PASS), and the maximal outcome improvement (MOI) on adolescents following primary hip arthroscopy for femoroacetabular impingement syndrome (FAIS). Second, to determine risk factors for revision surgery. Methods Prospectively collected data from two high‐volume hip arthroscopy centers were retrospectively reviewed on adolescents (≤19 years old) who underwent primary hip arthroscopy between November 2008 and February 2019. Adolescents with a minimum 2‐year follow‐up for the modified Harris Hip Score (mHHS), Non‐Arthritic Hip Score (NAHS), Hip Outcome Score‐Sports Specific Subscale (HOS‐SSS), International Hip Outcome Tool‐12 (iHOT‐12), and visual analog scale (VAS) for pain were included regardless of their growth plate status. Exclusion criteria were Tönnis grade >1, lateral center edge‐angle <18°, and previous ipsilateral hip surgery or conditions. Preoperative and postoperative radiographic data, MCID, PASS, MOI, secondary surgeries, and complications were reported. A multivariable survival analysis for risk factors for secondary surgery was conducted. Results A total of 287 hips (249 patients) were included (74.9% females). The mean values for age, body mass index, and follow‐up were 16.3 ± 1.3 years, 22.3 ± 3.5, and 26.6 ± 9.4 months, respectively. Further, 88.9% underwent labral repair, 81.5% femoroplasty, and 85.4% capsular closure. Improvement for all PROs was reported ( P < .001) with high patient satisfaction (8.8 ± 1.5). Achievement for the MCID was 71.7%, 83.0%, 68.1%, and 79.5% for the mHHS, NAHS, HOS‐SSS, and iHOT‐12, respectively. Achievement for the PASS was 68.3% for the mHHS and 73.2% for the NAHS. The MOI for mHHS, NAHS, and VAS was 58.3%, 77.0%, and 59.6%, respectively. Rates of revision hip arthroscopy, cam recurrence, and heterotopic ossification were 5.8%, 1.7%, and 5.5%, respectively. Acetabular retroversion was found to be a risk factor for revision surgery ( P = .03). Conclusion The results of this multi‐center study demonstrated that adolescents who underwent primary hip arthroscopy for FAIS reported significant improvement in all PROs, with satisfactory achievement rates for the MCID, PASS, MOI, and high patient satisfaction at a minimum 2‐year follow‐up. Level of Evidence IV, retrospective multicenter study.
Staged Bilateral Hip Arthroscopy for Femoroacetabular Impingement Syndrome: Index Surgery Patient Reported Outcome Measures Predict Contralateral Surgery Results at 2 Years
Horner, Nolan S. , Rice, Morgan W. , Alter, Thomas D. , Ephron, Christopher G. , Nho, Shane J. , Alter, Thomas, Sivasundaram, Lakshmanan

Mayo Clinic

Arthroscopy | December 8, 2022 | Volume: 39 | Issue: 5 | Pages: 1175

10.1016/j.arthro.2022.10.048 | PMID 36653274 Get It

Purpose To determine whether (1) patient‐reported outcome (PRO) scores after index hip arthroscopy correlate with PRO scores for the contralateral hip in patients undergoing staged bilateral hip arthroscopy and (2) patients who achieved minimal clinically important difference (MCID) or patient‐acceptable symptom state (PASS) for the index hip were more likely to achieve MCID or PASS for the contralateral hip. Methods Patients who underwent staged bilateral hip arthroscopy for femoroacetabular impingement syndrome were retrospectively reviewed. PRO scores were prospectively collected at preoperative and 1‐ and 2‐year timepoints. Odds ratios for achievement of MCID and PASS for the contralateral hip given achievement for the index hip were calculated. Improvements from before surgery to 2 years after surgery were correlated between both hips. Results A total of 143 patients (286 hips) were included in the final analysis. Average time between surgeries was 8.5 months (range, 0.7‐57.2). Both hips demonstrated significant improvement ( P < .05 for all) in all PROs at 2 years. Achievement of MCID in Hip Outcome Score Activities of Daily Living (HOS‐ADL) at the 1‐year timepoint for the index hip was predictive of achievement of MCID in HOS‐ADL at 2 years for the contralateral hip. Achievement of PASS in all PROs at the 1‐year timepoint for the index hip were predictive of achievement of PASS in the equivalent outcome score at the 2‐year mark for the contralateral hip. Achievement of MCID or PASS at the 2‐year timepoint for the index hip was predictive of achievement of the equivalent outcome at the 2‐year timepoint for the contralateral hip. The strongest correlation between improvement in PRO scores for the index and contralateral hips was noted in patients who underwent staged hip arthroscopy within less than 3 months. Conclusion Patients experience significant clinical benefit in both hips after staged bilateral hip arthroscopy. Results from the initial hip arthroscopy at either 1‐ or 2‐year follow‐up can be used to predict outcomes on the contralateral side; however, there is a higher degree of predictive value using 2‐year results. Average correlations between 2‐year PROs on the index and contralateral hips were moderate to strong, regardless of the time between surgeries. Level of Evidence Level III, retrospective cohort study.
Common Data Elements Reported in Mechanical Thrombectomy for Acute Ischemic Stroke: A Systematic Review of Active Clinical Trials
Ghozy, Sherief , Hardy, Nicole , Sutphin, Daniel J., Kadirvel, Ramanathan , Kallmes, David F. , Ghozy, Sherief , Kallmes, Kevin M

Mayo Clinic

Brain Sciences | December 8, 2022 | Volume: 12 | Issue: 12 | Pages: 1679

10.3390/brainsci12121679 | PMID 36552140 Get It

Background: New trials are planned regularly to provide the highest quality of evidence and invade new occlusion territories, which requires a pre-defined reporting strategy with consistent, common data elements for more straightforward collective evidence synthesis. We sought to review all active endovascular thrombectomy trials to investigate their patient selection criteria, intervention description, and reported outcomes. Methods: A literature search was systematically conducted on clinicaltrials.gov for active trials and all intervention, inclusion criteria, and outcomes reported were extracted. A qualitative synthesis of the frequency of study design types and data elements are graphically and narratively presented. Results: A total of 32 studies were tagged and included in the final qualitative analysis. The inclusion criteria were highly variable, including different cut-offs for the last well-known baseline National Institutes of Health Stroke Scale, Alberta Stroke Program Early CT Score, and modified Rankin scale (mRS). Half of the studies (16/32) mentioned “thrombectomy” without defining which technique or device was used, and the final thrombolysis in cerebral infarction scale was provided in 19 (59.4%) studies. Heterogeneity was also present among the studies reporting a first-pass effect, both in how studies defined the outcome and in used ranges for mRS. Mortality and intracerebral hemorrhage (ICH) were more homogenous in their presentation and follow-up. Conclusions: There is a great degree of heterogeneity in the active thrombectomy trials concerning inclusion criteria, interventions used, and how outcomes are being reported.